![The Hydrus Microstent Mechanisms of Actions & Clinical Efficacy](/sites/g/files/rbvwei1736/files/styles/news_195_260/public/2024-07/Screenshot%202024-07-16%20at%201.19.44%E2%80%AFPM_0.png?h=187d6222&itok=rTWZE5LO)
![](/sites/g/files/rbvwei1736/files/2024-07/Screenshot%202024-07-16%20at%201.19.44%E2%80%AFPM_0.png)
KEY TAKEAWAY POINTS
• The evolution of surgical glaucoma treatment has led to the development of procedures attempting to achieve better efficacy, but having variable complication profiles
• MIGS devices have the capacity to provide efficacy and reduce complications with rapid patient recovery
• The HYDRUS Microstent has a Tri-Modal® mechanism of action that bypasses the trabecular meshwork, scaffolds Schlemm’s canal, and spans approximately 90° ensuring access to collector channels in the nasal region
• The pivotal clinical data demonstrate that combining the HYDRUS Microstent with cataract surgery provides a durable decrease in IOP in adults with mild to moderate primary open-angle glaucoma with a concurrent decrease in medication dependence